NY-JEFFERIES-FINANCIAL
5.2.2024 12:46:33 CET | Business Wire | Press release
Jefferies Financial Group Inc. (NYSE: JEF) announced today that, consistent with its strategy to build the leading independent global Investment Banking and Capital Markets firm, Jefferies agreed to the sale by OpNet S.p.A (the Italian wireless broadband provider formerly known as Linkem) of substantially all of OpNet’s operations to Wind Tre S.p.A., a subsidiary of CK Hutchison Group Telecom Holdings Ltd. (CKHGT).
Under the terms of this sale agreement, the consideration will be €485 million, subject to certain adjustments, that will consist of cash in an amount sufficient to satisfy all of OpNet’s financial debt, transaction costs and other cash obligations and approximately €225 million to be paid also in cash or, at CKHGT’s election, in three-year notes issued by CKHGT that are similar to CKHGT’s publicly listed investment-grade bonds and are marketable. In addition to the consideration of the CKHGT notes, OpNet will retain majority ownership in other operating telecom companies, resulting in approximately €320 million in final value to Jefferies from this transaction, which exceeds our current carrying value. This sale is subject to regulatory approvals and is anticipated to close in the second or third quarter of 2024.
Jefferies recently agreed to sell Foursight Capital LLC (an automobile finance company) to One Main Holdings, Inc. (NYSE:OMF), and Golden Queen (a gold and silver mining company) to Andean Precious Metals (TXV:APM).
To reflect the completion of the substantial reduction of these legacy investments, Jefferies will reclassify the remaining legacy investments as “Other investments” in its Asset Management reportable segment in fiscal 2024. The only individual investment of size today is HomeFed, our real estate development company that specializes in mixed-use, master-planned communities. We expect to operate the core business of HomeFed, which has solid long-term prospects, and to liquidate certain peripheral assets in an orderly manner.
Rich Handler, CEO of Jefferies, and Brian Friedman, President of Jefferies, commented: “After over a decade of optimizing and efficiently monetizing our merchant banking assets and using the proceeds to reinvest in Jefferies and return capital to our shareholders, we are thrilled to be back to our roots of focusing exclusively on building the very best ‘pure play’ global investment banking firm. With the support of our more than 5,500 employee-partners worldwide, we have been able to achieve our goal of focusing Jefferies’ efforts on our core business, becoming a leader around the world in Investment Banking and Capital Markets. And we believe our human capital investment to broaden and deepen our capabilities, together with our Strategic Alliance with SMBC, position us well as we move forward in 2024 and the years beyond.”
About Jefferies
Jefferies (NYSE: JEF) is a leading global, full-service investment banking and capital markets firm that provides advisory, sales and trading, research, wealth, and asset management services. With more than 40 offices around the world, we offer insights and expertise to investors, companies and governments. For more information: www.jefferies.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements about our future and statements that are not historical facts. These forward‐looking statements are typically identified by such words as “believe,” “expect,” “anticipate,” “may,” “intend,” “outlook,” “will,” “estimate,” “forecast,” “project,” “should,” and other similar words and expressions, and are subject to numerous assumptions, risks and uncertainties, which will change over time. Forward-looking statements may contain beliefs, goals, intentions and expectations regarding revenues, earnings, operations, arrangements and other results, and may include statements of future performance, plans, and objectives. Forward-looking statements also include statements pertaining to our strategies for future development of our businesses and products. Forward‐looking statements speak only as of the date they are made; we do not assume any duty, and do not undertake, to update any forward‐looking statements. Furthermore, because forward‐looking statements represent only our belief regarding future events, many of which by their nature are inherently uncertain, the actual results or outcomes may differ, possibly materially, from the anticipated results or outcomes indicated in these forward-looking statements. Information regarding important factors, including Risk Factors that could cause actual results or outcomes to differ, perhaps materially, from those in our forward-looking statements is contained in reports we file with the SEC. You should read and interpret any forward-looking statement together with reports we file with the SEC. Past performance may not be indicative of future results. Different types of investments involve varying degrees of risk. Therefore, it should not be assumed that future performance of any specific investment or investment strategy will be profitable or equal the corresponding indicated performance level(s).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240131906401/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
One Biosciences Receives €3,3 Million Funding Under i-Démo 5 From France 2030 to Accelerate Development of First Single-Cell Diagnostic for Triple-Negative Breast Cancer, in Collaboration With Institut Curie10.9.2026 13:02:00 CEST | Press release
One Biosciences, a techbio company spun off from Institut Curie pioneering clinical-grade single-cell tumor profiling, and Institut Curie, the leading French center for the fight against cancer, today announced support from Bpifrance through the France 2030 i-Démo1 program for the CAST project (Cancer Single-cell Analysis for Therapy), securing €3,3 Million in funding. This milestone marks a major step forward in the development of single-cell tumor profiling technology for routine cancer care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260910763012/en/ Triple-negative breast cancer (TNBC) represents approximately 15–20% of breast cancer cases. Patients face high relapse rates, rapid disease progression and limited treatment options, while clinicians still lack reliable biomarkers to predict which patients will respond to immunotherapy or chemotherapy combinations. Current diagnostic approaches average signals across mil
New WSJ Intelligence Survey Highlights the Human Skills Companies Must Protect as AI Enters the Workplace10.9.2026 13:00:00 CEST | Press release
The Cognition Index Research Report, launched in partnership with Philip Morris International, warns of “Cognitive Atrophy” and a growing AI trust gap in the workplace Philip Morris International (PMI) (NYSE: PM) and WSJ Intelligence, the in-house thought leadership consultancy for The Wall Street Journal's commercial sales organization, today unveiled The Cognition Index Research Report, a comprehensive study exploring the evolving role of human cognition in an AI-driven workplace. Surveying more than 2,500 business professionals across the United States, United Kingdom, Italy, South Africa, and Brazil, the report reveals that while business professionals are increasingly optimistic about AI’s role in improving decision-making, they continue to see human judgment, ethics, critical thinking and empathy as essential capabilities that must be actively protected and developed as AI becomes embedded in workplace workflows. “Human cognition is a bit like a muscle: use it or lose it,” says M
Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training10.9.2026 12:35:00 CEST | Press release
Five organizations awarded grants, above the planned three, as a result of a competitive selection process with highly qualified applicants Training guidance is designed to prepare healthcare providers to deliver high-quality treatment experiences to patients receiving COMP360, if approved Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today the U.S. grant program recipients to create training programs for healthcare providers (HCPs) that will be involved in the delivery of psychedelic treatments, such as COMP360 psilocybin. These programs are intended to address both the need for foundational training in psychedelics, as well as ensuring HCPs are well-prepared to care for patients receiving treatment with COMP360 following its expected commercial launch, if approved. The recipients were selected through a competitive application process based on their expertise and proven abilit
Compass Pathways to Participate in Investor Conferences the Week of September 14th10.9.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will participate in the following investor conferences the week of September 14th: H.C. Wainwright Annual Global Investment Conference – New York, NY: Fireside chat at 3:30pm ET on September 15, 2026 Morgan Stanley 24th Annual Global Healthcare Conference – New York, NY: Fireside chat at 11:30am ET on September 16, 2026 Deutsche Bank’s 2026 Healthcare Summit – New York, NY: Fireside chat at 11:00am ET on September 17, 2026 A live audio webcast of the fireside chats will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlockin
GasEntec Announces New Ownership Structure, Accelerating Next Phase of Global Growth10.9.2026 11:00:00 CEST | Press release
Independent LNG infrastructure and technology company expands investment in proprietary technology, modular solutions and global project development. GasEntec Holdings Inc., a global LNG technology and assets company, today announced a new ownership structure designed to accelerate GasEntec’s next phase of growth and expand the commercialization of its proprietary LNG technologies and solutions. A consortium led by the Groupe Mimran has acquired a majority stake in GasEntec Holdings Inc., the US holding company, supporting GasEntec’s global growth. Under the new structure, GasEntec Holdings is the parent company of GasEntec’s South Korean operating business. Prior shareholders have exited in full. GasEntec’s customer relationships, contracts, engineering organization and ongoing global operations remain unchanged. GasEntec will continue to operate independently, with its technology development, engineering and operations centered in South Korea and an expanding commercial presence acro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
